(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 January 2017 (05.01.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/001990 A1

(51) International Patent Classification:
A61K 38/00 (2006.01) *C07K 14/705* (2006.01)
A61K 38/18 (2006.01) *C07K 19/00* (2006.01)

(21) International Application Number:
PCT/IB2016/053794

(22) International Filing Date:
24 June 2016 (24.06.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/185,716 28 June 2015 (28.06.2015) US

(71) Applicant: **ALLGENESIS BIOTHERAPEUTICS INC.** [CN/CN]; 7F-1, No. 760, Section 4, Bade Road, Songshan District, Taipei City, Taiwan 105 (CN).

(72) Inventors: **WU, Pei-Tzu**; 7F-1, No. 760, Section 4, Bade Road, Songshan District, Taipei City, Taiwan 105 (CN). **SHIU, Jia-Hau**; 7F-1, No. 760, Section 4, Bade Road, Songshan District, Taipei City, Taiwan 105 (CN). **CHERUKURY, Madhu**; 7F-1, No. 760, Section 4, Bade Road, Songshan District, Taipei City, Taiwan 105 (CN). **NGUYEN, Tan**; 7F-1, No. 760, Section 4, Bade Road, Songshan District, Taipei City, Taiwan 105 (CN). **ZEN, Kevin**; 7F-1, No. 760, Section 4, Bade Road, Songshan District, Taipei City, Taiwan 105 (CN).

(74) Agents: **QIN, Haiou** et al.; Alston & Bird LLP, 101 South Tryon Street, Bank of America Plaza, Suite 4000, Charlotte, North Carolina 28280-4000 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: FUSION PROTEINS FOR INHIBITING ANGIOGENESIS



FIG. 1

(57) **Abstract**: The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.

WO 2017/001990 A1